Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +49.81%
#3 Glidr Glidr +36.41%
#4 Walrus Walrus +33.05%
#5 Cysic Cysic +22.50%
#6 The Black Bull The Black Bull +19.10%
#7 Tutorial Tutorial +16.25%
#8 Humanity Humanity +14.61%
#9 Nockchain Nockchain +14.30%
#10 Plume Plume +12.86%
Coin of the day
EXOD EXOD
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Impel Pharmaceuticals Inc. Impel Pharmaceuticals Inc.

Impel Pharmaceuticals Inc.

IMPL
Kedudukan dalam Saham #37159
Impel Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical... Impel Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical firm, concentrating its efforts on creating and commercializing therapies for individuals in the United States who are affected by central nervous system (CNS) conditions. Leading its product portfolio is Trudhesa, an innovative upper nasal formulation of dihydroergotamine, specifically engineered for the prompt relief of acute migraine attacks. Furthermore, the company's development pipeline encompasses INP105, another upper nasal medication containing olanzapine, currently being advanced for the rapid treatment of agitation and aggressive behaviors associated with autism spectrum disorder. Impel is also progressing with INP107, an intranasal carbidopa/levodopa compound, which has already successfully concluded its Phase IIa clinical trial aimed at managing "OFF" episodes in Parkinson's disease patients. Initially established in 2008, the company was formerly known as Impel NeuroPharma, Inc. before rebranding to Impel Pharmaceuticals Inc. in April 2022. Its corporate headquarters are situated in Seattle, Washington.
Harga Saham
$0.1011
Disegerakkan terakhir: 2024-01-16
Modal Pasaran
$1.96M
Perubahan (1 hari)
1.10%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Impel Pharmaceuticals Inc. (IMPL)

Kategori

Healthcare
Nisbah P/E bagi Impel Pharmaceuticals Inc. (IMPL)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Impel Pharmaceuticals Inc., nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Impel Pharmaceuticals Inc. dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.